ArticleHuman mutation2025
TCIRG1 as a Novel Prognostic Biomarker Triggering Immune Infiltration in Renal Clear Cell Carcinoma: An Integrative Study of Single-Cell and Bulk Data.
Article in Human mutation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular and Genetic Landscape of Intravenous Leiomyomatosis: A Narrative Review.Cancer innovation · 2026Review
- A single-cell and machine learning framework identifies CAFs-associated signatures linking stromal heterogeneity to immune regulation in pancreatic cancer.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor microenvironment (TME) is a significant factor regulating the malignant phenotype and drug resistance of kidney renal clear cell carcinoma (KIRC). The identification of biomarker signatures mediating immune infiltration in TME is of significance for prognostic assessment and personalized therapy of KIRC. Methods: The gene set associated with immune cell populations in KIRC TME was extracted from the single-cell dataset GSE139555 using high-dimensional weighted coexpression network analysis (hdWGCNA). The bulk data from TCGA-KIRC were integrated to screen significant signatures in KIRC prognosis through Cox regression, and a combination of 101 machine learning algorithms was compared to prioritize feature genes for the construction of a novel prognostic model. Finally, LightGBM and XGBoost algorithms identified TCIRG1 as a key model feature and a novel biomarker in KIRC for experimental characterization using western blot, immunohistochemistry, multiple immunofluorescence (mIHC), subcutaneous tumor formation in nude mice, and Transwell assays. Results: Single-cell data showed that the monocyte population varied most significantly in KIRC samples, and 150 candidate genes from monocytes were identified based on hdWGCNA. By integrating bulk TCGA-KIRC data and Cox regression, 15 prognosis-related genes were extracted as candidates for machine learning-powered training using 101 algorithm combinations, and nine genes were prioritized as feature variables to establish a prognostic model with good predictive performance on the overall survival of KIRC patients. Finally, TCIRG1 was identified as a novel biomarker signature from the prognostic model, and ultimately, by combining LightGBM and XGBoost algorithms, TCIRG1 was identified as a key characteristic signal for experimental validation and functional studies. Immunohistochemistry, cellular, and animal experiments showed that TCIRG1 expression was significantly elevated in KIRC samples, and its high expression was closely associated with adverse clinicopathological features. mIHC results demonstrated a significant positive correlation between TCIRG1 expression and immune cell infiltration in the KIRC TME, particularly with Treg cells. Conclusions: TCIRG1 was identified and validated as a novel prognostic biomarker triggering immune infiltration in KIRC. The mechanisms and translational prospects of TCIRG1 in KIRC management will be explored in future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.